Benefits and risks associated with continuation of anti–TNF after 24 weeks of pregnancy in inflammatory bowel disease.

Benefits and Risks Associated With Continuation of Anti–Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease – Annals of Internal Medicine (link to abstract – $ for full-text)

News Release: Anti-TNF continuation after 24 weeks of pregnancy beneficial to persons with IBD, does not affect neonatal outcomes – American College of Physicians

Commentary: Continuation of Anti-TNF for IBD After 24 Weeks of Pregnancy Beneficial – HealthDay

Commentary on Twitter

10 year trial found continuation of #AntiTNF treatment after 24 weeks of pregnancy appears beneficial for #IBD activity and prematurity, not affecting neonatal outcomes and serious infections in the offspring. @EPIPHARE https://t.co/YuytSQqDsE pic.twitter.com/CRGN80K93A

— Annals of Int Med (@AnnalsofIM) September 27, 2022